Are Inflammatory Markers Significant Prognostic Factors for Head and Neck Cancer Patients?

Area of Science:

• Oncology
• Inflammation Research
• Cancer Biomarkers

Background:

• Conflicting reports exist on inflammatory markers and outcomes in head and neck cancer (HNC).
• Platelets and inflammatory markers are implicated in solid tumour treatment outcomes.
• Pre-treatment inflammatory markers require further investigation as prognostic tools in HNC.

Purpose of the Study:

• To determine if pre-treatment inflammatory markers, specifically platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR), can predict overall survival and tumour control in HNC patients.
• To evaluate the prognostic value of PLR and NLR in head and neck cancer.
• To establish pre-treatment inflammatory markers as potential prognostic tools for HNC.

Main Methods:

• Retrospective analysis of 147 HNC patients treated between 2014 and 2018.
• Evaluation of pre-treatment platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR).
• Statistical analysis to determine the association between PLR, NLR, and patient outcomes, with optimal cut-offs established at >200 for PLR and >2.85 for NLR.

Main Results:

• Higher PLR was associated with a nearly 3-fold increased risk of mortality (HR 2.79, p < 0.01).
• Higher NLR was associated with a 2.5-fold increased risk of mortality (HR 2.62, p = 0.02).
• These associations remained significant after adjusting for age, disease stage, and treatment modality.

Conclusions:

• Elevated pre-treatment PLR and NLR are significant predictors of poor overall survival in HNC patients.
• PLR and NLR can serve as valuable prognostic biomarkers for head and neck cancer.
• These findings support the use of inflammatory markers in predicting treatment outcomes for HNC patients receiving surgery or chemoradiotherapy.